Diagnostic Center | June 26, 2024
Imfinzi improved event-free survival and overall survival for bladder cancer
First immunotherapy regimen before and after surgery to extend survival in bladder cancer
First immunotherapy regimen before and after surgery to extend survival in bladder cancer
First and only BTK inhibitor to demonstrate favourable overall survival trend vs. standard-of-care chemoimmunotherapy in this setting
Recommendation based on FLAURA2 results which showed Tagrisso plus chemotherapy extended median progression-free survival by nearly 9 months
Back-to-back plenary presentations for LAURA and ADRIATIC Phase III trials reinforce the potential of Tagrisso and Imfinzi in early lung cancer settings
First BTK inhibitor to show favourable trend in overall survival vs. standard-of-care chemoimmunotherapy in this setting
Recommendation based on CAPItello-291 results which showed the Truqap combination reduced the risk of disease progression or death by 50%
Longest survival follow-up ever reported for immunotherapy treatment in this setting
First and only immunotherapy to demonstrate survival benefit in this setting in a global Phase III trial
Application based on results from the TROPION-Breast01 Phase III trial
Combination shows consistent benefit across prespecified post-progression outcomes
Subscribe To Our Newsletter & Stay Updated
